Herpes zoster, commonly known as shingles, is caused by the reactivation of the varicella-zoster virus, the same virus that causes chickenpox. It typically presents as a painful skin rash and may lead to severe complications, especially in older adults. GlaxoSmithKline's Shingrix, approved in 2017, is considered effective in preventing shingles and its associated complications.
The company we are profiling today is Dynavax Technologies Corp. (DVAX), which is also developing a shingles vaccine.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com